As we sort through the results of the recent election, one thing that should be noted is what didn’t happen. The Biden-Harris Administration, despite intense pressure from its progressive allies, never finalized the pending march in guidelines. The draft guidelines, which issued late last year, were an attempt to misuse the landmark Bayh-Dole Act so the government could micro-manage the price of products based on federally-funded inventions. Critics of Bayh-Dole have tried for 20 years to turn the law, designed to decentralize technology management from Washington into the hands of those who make inventions in our public research institutions and companies, on its head so Washington could regulate prices.
Recent Posts
- Latest Trump Executive Order Redirects Drug Pricing Debate
- Lutnick Tells Inventors, ‘You Have a Friend’ at Commerce
- Other Barks & Bites for Friday, May 9: USPTO Responds to GAO Report; Stewart Welcomes National Inventors Hall of Fame Inductees; CAFC Defines ‘Ground’ for IPR Estoppel Statute
- PTAB Designates as Informative Stewart Decision on Discretion to Institute in Context of Parallel District Court Litigation
- Judge Hughes Again Calls Out CAFC’s Overly Rigid Article III Analysis for Pharmaceutical Cases